SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that it has achieved a $2.5 million regulatory milestone under its over-the-counter (OTC) license agreement with Schering-Plough Healthcare Products, Inc. Santarus expects to receive the $2.5 million payment within the next two weeks. Schering-Plough is seeking U.S. Food and Drug Administration (FDA) approval to sell a ZEGERID® branded omeprazole/sodium bicarbonate OTC product. The OTC heartburn market in 2007 was estimated at $1.6 billion in the U.S. based on data from external market research sources and Santarus estimates.
